DE69607191D1 - Spezifische bindungspartner für menschlichen transformierenden wachstumsfaktor und verfahren - Google Patents

Spezifische bindungspartner für menschlichen transformierenden wachstumsfaktor und verfahren

Info

Publication number
DE69607191D1
DE69607191D1 DE69607191T DE69607191T DE69607191D1 DE 69607191 D1 DE69607191 D1 DE 69607191D1 DE 69607191 T DE69607191 T DE 69607191T DE 69607191 T DE69607191 T DE 69607191T DE 69607191 D1 DE69607191 D1 DE 69607191D1
Authority
DE
Germany
Prior art keywords
specific binding
tgf beta
growth factor
transforming growth
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69607191T
Other languages
English (en)
Other versions
DE69607191T2 (de
Inventor
Elizabeth Thomson
John Vaughan
James Williams
Alexander Green
Henry Jackson
Louise Bacon
Stuart Johnson
Jane Wilton
Ronald Tempest
Richard Pope
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9520486.3A external-priority patent/GB9520486D0/en
Application filed by Cambridge Antibody Technology Ltd filed Critical Cambridge Antibody Technology Ltd
Publication of DE69607191D1 publication Critical patent/DE69607191D1/de
Application granted granted Critical
Publication of DE69607191T2 publication Critical patent/DE69607191T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69607191T 1995-10-06 1996-10-07 Spezifische bindungspartner für menschlichen transformierenden wachstumsfaktor und verfahren Expired - Lifetime DE69607191T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9520486.3A GB9520486D0 (en) 1995-10-06 1995-10-06 Specific binding members for human transforming growth factor beta; materials and methods
GBGB9601081.4A GB9601081D0 (en) 1995-10-06 1996-01-19 Specific binding members for human transforming growth factor beta;materials and methods
PCT/GB1996/002450 WO1997013844A1 (en) 1995-10-06 1996-10-07 Specific binding members for human transforming growth factor beta; materials and methods

Publications (2)

Publication Number Publication Date
DE69607191D1 true DE69607191D1 (de) 2000-04-20
DE69607191T2 DE69607191T2 (de) 2000-09-28

Family

ID=26307896

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69607191T Expired - Lifetime DE69607191T2 (de) 1995-10-06 1996-10-07 Spezifische bindungspartner für menschlichen transformierenden wachstumsfaktor und verfahren
DE69611766T Expired - Lifetime DE69611766T2 (de) 1995-10-06 1996-10-07 Spezifische Bindungspartner für menschliches TGF-beta, Materialien und Verfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69611766T Expired - Lifetime DE69611766T2 (de) 1995-10-06 1996-10-07 Spezifische Bindungspartner für menschliches TGF-beta, Materialien und Verfahren

Country Status (12)

Country Link
EP (2) EP0853661B1 (de)
JP (1) JP4387458B2 (de)
AT (2) ATE190650T1 (de)
AU (1) AU702049B2 (de)
CA (2) CA2233042C (de)
DE (2) DE69607191T2 (de)
DK (2) DK0945464T3 (de)
ES (2) ES2156035T3 (de)
GB (2) GB9601081D0 (de)
GR (2) GR3033436T3 (de)
PT (2) PT853661E (de)
WO (1) WO1997013844A1 (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
AU5087799A (en) 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
EP1166112A4 (de) * 1999-04-09 2004-11-10 Hanmi Pharm Ind Co Ltd Verfahren zum quantifizieren von tgf-beta und verfahren zum nachweis von krebs
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1486560A3 (de) * 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Antikörper und Antikörperfragmente mit Spezifizität für TGF beta 1
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001027621A2 (en) * 1999-10-07 2001-04-19 Pharmacia Corporation Competitive inhibition elisa for antibody detection
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
EP2281843B1 (de) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Immunspezifisch bindende antikörper gegen BLyS
EP1339847A2 (de) * 2000-11-28 2003-09-03 Amgen, Inc. Transformierender wachstumsfaktor beta-verwandte moleküle und ihre verwendung
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
AU2002250032B2 (en) * 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
DE10210427A1 (de) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
CA2481747A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003249533A1 (en) 2002-07-04 2004-01-23 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
CA2502367C (en) 2002-10-16 2013-12-10 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
GB0224436D0 (en) * 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
US20050221383A1 (en) 2003-08-08 2005-10-06 Choong-Chin Liew Osteoarthritis biomarkers and uses thereof
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
AU2005230848B9 (en) 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006086242A2 (en) 2005-02-07 2006-08-17 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
HUE042689T2 (hu) 2005-02-08 2019-07-29 Genzyme Corp TGFbéta elleni antitestek
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
EP1858545A2 (de) 2005-03-04 2007-11-28 Curedm Inc. Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
ATE505489T1 (de) 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
EP2295066B1 (de) 2005-05-25 2016-04-27 CureDM Group Holdings, LLC Peptide, Derivate und Analoge davon sowie Verfahren zu ihrer Anwendung
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
EP1945816B1 (de) 2005-10-21 2011-07-27 GeneNews Inc. Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
JP5602365B2 (ja) 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
EP1998810A4 (de) 2006-03-13 2009-09-02 Univ Johns Hopkins Erhöhung der endothelialen thromboresistenz
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
PL2083863T3 (pl) 2006-10-03 2015-08-31 Genzyme Corp Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
EP2077859A4 (de) 2007-03-30 2010-11-24 Medimmune Llc Antikörper-formulierung
RU2549701C2 (ru) 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
NO3072525T3 (de) 2007-05-14 2018-06-30
MX337147B (es) 2007-08-30 2016-02-15 Curedm Group Holdings Llc Composiciones y metodos para utilizar peptidos proislet y sus analogos.
DK2219452T3 (en) 2007-11-05 2016-01-11 Medimmune Llc PROCESSES FOR THE TREATMENT OF scleroderma.
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
MX2010007767A (es) 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
WO2009100309A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2363471B1 (de) 2008-10-31 2016-10-12 Toray Industries, Inc. Immunoassayverfahren für menschliches cxcl1-protein
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
CA2770737C (en) 2009-08-13 2020-05-12 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP3117709B1 (de) 2010-03-12 2018-08-01 Genzyme Corporation Kombinationstherapie zur behandlung von brustkrebs
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012090997A1 (ja) 2010-12-27 2012-07-05 京都府公立大学法人 ｉＰＳ細胞とその製造法
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2799537B1 (de) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
EP2953634B1 (de) 2013-02-07 2021-05-26 The General Hospital Corporation Verfahren zur expansion oder abreicherung von t-regulatorischen zellen
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
AR095240A1 (es) 2013-03-11 2015-09-30 Genzyme Corp ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS
KR102168088B1 (ko) 2013-03-14 2020-10-20 더 브리검 앤드 우먼즈 하스피털, 인크. 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
JP6519056B2 (ja) 2013-10-01 2019-05-29 東レ株式会社 膵腫瘍の検出方法、抗体及び膵腫瘍検出用キット
EP3804760A1 (de) 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Therapeutikum für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
TWI774071B (zh) 2014-10-01 2022-08-11 英商梅迪繆思有限公司 針對替格瑞洛的抗體及使用方法
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
EP3237450B1 (de) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
DK3252474T3 (da) 2015-01-26 2020-11-09 Toray Industries Fremgangsmåde og kit til detektering af galdevejskræft
WO2016140210A1 (ja) 2015-03-02 2016-09-09 東レ株式会社 膵臓機能異常の検出方法及び検出用キット
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
CN113603784A (zh) 2015-05-29 2021-11-05 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
MX2018002315A (es) 2015-09-01 2018-04-11 Agenus Inc Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
SG11201805941WA (en) 2016-02-17 2018-09-27 Novartis Ag Tgfbeta 2 antibodies
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11643459B2 (en) * 2016-03-11 2023-05-09 Scholar Rock, Inc. TGFβ1-binding immunoglobulins and use thereof
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
MX2018014047A (es) 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
JP7267012B2 (ja) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド 抗ｔｉｍ－３抗体及びその使用方法
JP2019525772A (ja) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
TWI832600B (zh) 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
SI3618863T1 (sl) 2017-05-01 2023-12-29 Agenus Inc. Protitelesa proti tigitu in načini uporabe njih
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN111094352A (zh) 2017-08-25 2020-05-01 戊瑞治疗有限公司 B7-h4抗体及其使用方法
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
EP3707510B1 (de) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnose- und therapieverfahren für krebs
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
KR102661891B1 (ko) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
EP3837352A1 (de) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Zusammensetzungen und verfahren zur erzeugung von haarzellen durch hochregulieren von jag-1
EP3856773A1 (de) 2018-09-28 2021-08-04 Kyowa Kirin Co., Ltd. Il-36-antikörper und verwendungen davon
CA3113575A1 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CA3124356A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
CN114641501A (zh) 2019-09-04 2022-06-17 Y生物股份有限公司 抗vsig4抗体或抗原结合片段及其用途
CN112852738B (zh) * 2019-11-27 2023-02-28 四川省肿瘤医院 一种前列腺癌细胞膜片的制备方法
BR112022016368A2 (pt) 2020-02-18 2023-01-10 Alector Llc Anticorpos pilra e seus métodos de uso
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
JP2023528235A (ja) 2020-05-17 2023-07-04 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
CN116507636A (zh) 2020-07-20 2023-07-28 阿斯利康(英国)有限公司 SARS-CoV-2蛋白、抗SARS-CoV-2抗体以及它们的使用方法
KR20230048439A (ko) 2020-08-18 2023-04-11 세파론 엘엘씨 항-par-2 항체 및 이의 사용 방법
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
AU2021390501A1 (en) 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
KR20230156727A (ko) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
CN117063070A (zh) 2021-03-24 2023-11-14 东丽株式会社 恶性胰腺囊性肿瘤的判定辅助方法和判定辅助用试剂盒
EP4348263A1 (de) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Verfahren zum nachweis von cm-tma-biomarkern
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
KR20240042476A (ko) 2021-07-30 2024-04-02 오엔에이 테라퓨틱스 에스.엘. 항-cd36 항체 및 암을 치료하기 위한 이의 용도
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
CA2065860C (en) * 1989-09-29 2001-03-27 Wayne A. Border Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
NZ282856A (en) * 1994-03-29 1998-06-26 Univ Manchester Promoting wound healing using an agent (antibody) specific to a growth factor or associated protein
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition

Also Published As

Publication number Publication date
GB2305921B (en) 1999-10-20
CA2233042C (en) 2007-12-18
DE69611766T2 (de) 2001-08-02
AU702049B2 (en) 1999-02-11
JP2000500643A (ja) 2000-01-25
DK0853661T3 (da) 2000-08-14
EP0853661B1 (de) 2000-03-15
DE69611766D1 (de) 2001-03-15
GR3033436T3 (en) 2000-09-29
AU7140596A (en) 1997-04-30
GB2305921A (en) 1997-04-23
ATE190650T1 (de) 2000-04-15
EP0945464A1 (de) 1999-09-29
DK0945464T3 (da) 2001-05-07
JP4387458B2 (ja) 2009-12-16
PT853661E (pt) 2000-08-31
PT945464E (pt) 2001-07-31
GB9620920D0 (en) 1996-11-27
ES2156035T3 (es) 2001-06-01
DE69607191T2 (de) 2000-09-28
WO1997013844A1 (en) 1997-04-17
GR3035775T3 (en) 2001-07-31
ATE199091T1 (de) 2001-02-15
CA2599488A1 (en) 1997-04-17
CA2233042A1 (en) 1997-04-17
EP0945464B1 (de) 2001-02-07
ES2146020T3 (es) 2000-07-16
EP0853661A1 (de) 1998-07-22
GB9601081D0 (en) 1996-03-20

Similar Documents

Publication Publication Date Title
DE69607191D1 (de) Spezifische bindungspartner für menschlichen transformierenden wachstumsfaktor und verfahren
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE154613T1 (de) Monoklonaler antikörper spezifisch für ein humanes atherom-assoziiertes antigen
MX9603773A (es) Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios.
NO973447L (no) Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi
SG50681A1 (en) Method for the production of monoclonal antibodies utilizing a germfree animal
DE68920693D1 (de) Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
ATE243745T1 (de) Bibliotheken aus polyklonalen antikörpern
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
FI964845A (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
EP0444856A3 (en) Diagnostic assay for alzheimer's disease
GR3025630T3 (en) Monoclonal antibody against human IgE
ATE193326T1 (de) Monoklonalantikörper, linker- und beta- glucuronidase enthaltende fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
DE3579808D1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
Jahn et al. Anti-Bacterial Reactivity of Human Monoclonal Polyspecific Natural IgM Antibodies—a Basic Defence Mechanism Against Infectious Agents
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии

Legal Events

Date Code Title Description
8364 No opposition during term of opposition